Atlas Trials

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Clinical trial NCT03126110 · COMPLETED

Trial details

NCT number
NCT03126110
Sponsor
Incyte Biosciences International Sàrl
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced MalignanciesMetastatic Cancer
Start date
2017-04-25
Primary completion
2021-11-09
Enrollment
145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.